Shares of Elan Corp. plc (NYSE: ELN) rallied more than 5% in Thursday's pre-market trading on speculation that the company could be a takeoever target. Shares of the company also rallied as UBS upgraded the stock to Buy from Neutral. The firm also added the stock to UBS's "Top 20 Key Calls List." Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, BioNeurology and Elan Drug Technologies (EDT). Stay tuned for more.
Full Disclosure: None.
